Radioisotopes in Drug Research and Development: Focus on Positron Emission Tomography

@inproceedings{Miyoshi2011RadioisotopesID,
  title={Radioisotopes in Drug Research and Development: Focus on Positron Emission Tomography},
  author={Sosuke Miyoshi and Keisuke Mitsuoka and Shintaro Nishimura and Stephan A. Veltkamp},
  year={2011}
}

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 66 REFERENCES

Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2009
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2008
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2008
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Aukema TS, Vogel WV, Hoefnagel CA, and Vald ́es Olmos RA

Format for NDAs, ANDAs, February
  • Prevention of Brown
  • 2011

Similar Papers

Loading similar papers…